Package Leaflet: Information for the User
Dormidinadoxilamine25 mg film-coated tablets
Doxylamine hydrogen succinate
Read all of this leaflet carefully before you start taking this medicine, because it contains important information for you.
Follow exactly the administration instructions of the medicine contained in this leaflet or as indicated by your doctor or pharmacist.
Contents of the Package Leaflet
5 Conservation of Dormidina doxylamine
Dormidina doxylamine is a medicine that contains the active ingredient doxylamine hydrogen succinate. Doxylamine belongs to a group of medicines called antihistamines, which have sedative properties.
It is indicated for the symptomatic treatment of occasional insomnia in adults over 18 years of age.
You should consult a doctor if your condition worsens or does not improve after 7 days.
Do not take Dormidinadoxylamine
Warnings and precautions
Consult your doctor or pharmacist before taking Dormidina doxylamine.
Taking Dormidinadoxylaminewith other medicines
Inform your doctor or pharmacist that you are taking, have recently taken, or may need to take any other medicine.
Do not take Dormidina doxylamine with the following medicines, as their effects may be enhanced:
Interference with diagnostic tests
Doxylamine may interfere with skin allergy tests that use allergens. It is recommended to discontinue treatment with Dormidina doxylamine at least three days before starting such tests.
Taking Dormidinadoxylaminewith food, drink, and alcohol
Alcoholic beverages should not be consumed during treatment with Dormidina doxylamine.
See section 3. How to take Dormidina doxylamine
Pregnancy,breastfeedingand fertility
Do not take Dormidina doxylamine if you are pregnant, plan to become pregnant, or are breastfeeding.
No data are available on the possible effects of Dormidina doxylamine on fertility.
Driving and using machines
The influence of Dormidina doxylamine on the ability to drive and use machines is significant. Do not drive or use hazardous machinery while taking this medicine, at least during the first days of treatment, until you know how it affects you.
Sodium content
This medicine contains less than 23 mg of sodium (1 mmol) per tablet; it is essentially "sodium-free".
Follow exactly the administration instructions of the medicine contained in this leaflet or as indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist.
Adults (over 18 years of age)
The recommended dose is 1 tablet (25 mg) per day.
If daytime drowsiness occurs, it is recommended to reduce the dose to 12.5 mg per day by taking Dormidinadoxylamine12.5 mg film-coated tabletsor to take it earlier to ensure that at least 8 hours pass until waking time.
Do not take more than 1 tablet (25 mg) per day.
Use in the elderly
People over 65 years of age are more likely to suffer from other diseases that may require a dose reduction. In case of unwanted side effects, it is recommended to reduce the dose to 12.5 mg per day by taking Dormidinadoxylamine12.5 mg film-coated tablets.
Use in patients with liver or kidney disease
These patients should take a different dose, adjusted to the degree of their disease, which will be determined by the doctor.
Use in children and adolescents
Dormidina doxylamine is not recommended for use in children under 18 years of age; therefore, this medicine should not be used in this population.
Route and method of administration
Oral route.
The tablets should be taken 30 minutes before bedtime with a sufficient amount of liquid (preferably water).
Dormidina doxylamine can be taken before or after meals.
Duration of treatment
The duration of treatment should be as short as possible. In general, the duration of treatment can range from a few days to a week.
It should not be administered for a period exceeding 7 days without consulting a doctor.
If you take more Dormidinadoxylaminethan you should
The symptoms of an overdose are: drowsiness, depression or stimulation of the central nervous system, anticholinergic effects (dilated pupils, fever, dry mouth, decreased intestinal tone), flushing, increased or altered heart rate, increased blood pressure, nausea, vomiting, agitation, altered gait, dizziness, irritability, sedation, confusion, and hallucinations. Delirium, psychosis, decreased blood pressure, convulsions, decreased respiration, loss of consciousness, coma, and death may occur. A serious complication can be rhabdomyolysis (muscle damage), followed by kidney failure.
There is no specific antidote for antihistamine overdose; therefore, treatment is symptomatic and supportive. Your doctor will assess the need to induce vomiting, perform a stomach wash, or prescribe medications to increase blood pressure if necessary.
In case of overdose or accidental ingestion, consult the Toxicology Information Service. Phone 91.562.04.20.
If you forget to take Dormidinadoxylamine
Do not take a double dose to make up for forgotten doses.
Take your dose at the usual time the next day.
If you stop taking Dormidinadoxylamine
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, Dormidina doxylamine can cause side effects, although not everybody gets them.
The side effects of doxylamine are generally mild and transient, being more frequent in the first days of treatment.
Common side effects (may affect up to 1 in 10 people): drowsiness and effects such as dry mouth, constipation, blurred vision, urinary retention, increased bronchial secretion, dizziness, headache, abdominal pain, fatigue, insomnia, and nervousness.
Uncommon side effects (may affect up to 1 in 100 people): asthenia (fatigue), peripheral edema (inflammation of arms and legs), nausea, vomiting, diarrhea, skin rash, tinnitus (ringing in the ears), orthostatic hypotension (decrease in blood pressure due to posture changes), diplopia (double vision), dyspepsia (stomach disorders), feeling of relaxation, nightmares, and dyspnea (breathing difficulties).
Rare side effects (may affect up to 1 in 1,000 people): agitation (especially in children and the elderly), tremors, convulsions, or blood disorders such as hemolytic anemia, thrombocytopenia, leukopenia, or agranulocytosis (decrease in certain blood cells).
Side effects of unknown frequency (cannot be estimated from available data): general malaise.
Other side effects that have occurred with the use of antihistamines in general, although not observed with doxylamine, are the following: arrhythmia (alteration of heart rate), palpitations, duodenogastric reflux, abnormal liver function (cholestatic jaundice), prolonged QT interval on the electrocardiogram (a cardiac disorder), decreased appetite, increased appetite, myalgia (muscle pain), abnormal coordination, extrapyramidal disorder (movement disorders), paresthesia (abnormal sensations), psychomotor activity impairment (coordination of senses and movement), depression, decreased bronchial secretion, alopecia (hair loss), allergic dermatitis, hyperhidrosis (excessive sweating), photosensitivity reaction, or hypotension (low blood pressure).
The frequency and magnitude of side effects can be reduced by decreasing the daily dose.
People over 65 years of age have a higher risk of experiencing adverse reactions, as they may have other diseases or be taking other medicines simultaneously. These people also have a higher risk of falls.
If you experience side effects, consult your doctor or pharmacist, even if they are not listed in this leaflet.
Reporting of side effects:
If you experience any side effects, consult your doctor, even if they are possible side effects that do not appear in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiration date stated on the carton or blister after EXP. The expiration date is the last day of the month indicated.
No special storage conditions are required.
Medicines should not be disposed of via wastewater or household waste. Place the packaging and any unused medicine in the SIGRE collection point at your pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and any unused medicine. This will help protect the environment.
Composition of Dormidinadoxylamine
Core excipients:
Calcium hydrogen phosphate dihydrate (E-341)
Microcrystalline cellulose (E-460)
Sodium carboxymethyl starch (type A) of potato
Colloidal anhydrous silica (E-551)
Magnesium stearate (E-572)
Coating excipients:
Microcrystalline cellulose (E-460)
Poloxamer 407 (E-431)
Propylene glycol (E-1520)
Hypromellose (E-464)
Titanium dioxide (E-171)
Polyethylene glycol 8000
Appearance of the product and contents of the pack
Dormidina doxylamine is presented in the form of white, film-coated, elongated tablets, in packs containing 7 or 14 tablets.
Only certain pack sizes may be marketed.
Marketing authorization holder and manufacturer
Marketing authorization holder
Esteve Pharmaceuticals, S.A.
Passeig de la Zona Franca, 109
08038 Barcelona
Spain
Manufacturer
Towa Pharmaceutical Europe, S.L.
c/ de Sant Martí, 75-97
08107 Martorelles (Barcelona)
Spain
Date of last revision of this leaflet: August 2012.
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS)http://www.aemps.gob.es/